ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1400

Hyperferritinemia and Fever in Adults

Kensuke Nakanishi and Mitsuyo Kinjo, Rheumatology, Okinawa Chubu Hospital, Uruma, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Adult-onset Still's disease, Fever, hemochromatosis and liver disease

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster Session II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Clinical associations of hyperferritinemia include: hepatocellular injury, hemophagocytic lymphohistiocytosis (HLH), hematologic malignancy, adult-onset Still’s disease (AOSD), and iron overload. Fever of undetermined origin (FUO) may or may not co-exist with hyperferritinemia in adults. The aim of this study was to describe the associations of with hyperferritinemia and FUO in adults.

Methods: We retrospectively identified patients >16 years old with serum ferritin levels > 5,000 μg/L at a tertiary medical center in Japan between 2002-2014. FUO was defined as temperature>38.3℃ with etiology undetermined after 3 days of in-hospital evaluation. Data were collected on clinical features, medications and mortality.

Results: We identified 156 Japanese patients with hyperferritinemia. Median age was 66 years (range, 16-95); 47% were female. Median serum ferritin level was 9,369μg/L (range, 5,000-170,202); Mortality during the admission was 42%. FUO was absent in 118/156 and present in 38/156 patients (Table). The most common diagnosis was hepatocellular injury, but this was rarely seen with FUO. Among those with FUO and elevated ferritin, hematologic malignancies, HLH, AOSD, and lupus (SLE) were diagnosed. HLH and AOSD remains most prevalent for patients with serum ferritin>10,000μg/L and FUO.

Conclusion: Although hyperferritinemia commonly indicates liver disease and hemochromatosis, clinicians should be aware that hyperferritinemia in conjunction with FUO is a reliable marker for more complex diagnoses such as HLH, AOSD or SLE, especially when ferritin levels are extremely high.

Table. Differential Diagnosis of Hyperferritinemia, by FUO status.

 

 

Diagnosis

No FUO

With FUO

 

No. (%)

No. (%)

Total

118

38

 Hepatocellular injury

57 (48)

2 (5)

 Iron overload

26 (22)

0 (0)

 Hemophagocytic lymphohistiocytosis

0 (0)

8 (21)

 Hematologic malignancies

12 (10)

9 (24)

 Bacterial infection

9 (8)

0 (0)

 Adult onset Still’s disease

0 (0)

8 (21)

 Systemic lupus erythematosus

0 (0)

4 (11)

 Viral infection

2 (2)

0 (0)

 Solid tumor

10 (8)

0 (0)

 Other

0 (0)

4 (11)

 Undetermined

1 (1)

3 (8)

* Castleman’s disease (2), miliary tuberculosis (1), dermatomyositis (1).

 

 


Disclosure: K. Nakanishi, None; M. Kinjo, None.

To cite this abstract in AMA style:

Nakanishi K, Kinjo M. Hyperferritinemia and Fever in Adults [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/hyperferritinemia-and-fever-in-adults/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hyperferritinemia-and-fever-in-adults/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology